Generic placeholder image

Current Drug Targets - Inflammation & Allergy


ISSN (Print): 1568-010X
ISSN (Online): 1568-010X

Therapeutic Blockade of TCR Signal Transduction and Co-Stimulation in Autoimmune Disease

Author(s): Laurence M. Howard, Adam P. Kohm, Carol L. Castaneda and Stephen D. Miller

Volume 4, Issue 2, 2005

Page: [205 - 216] Pages: 12

DOI: 10.2174/1568010053586228

Price: $65


Autoimmune diseases are initiated and maintained by presentation of self antigen through complex interactions between different cells of the immune system. In most autoimmune disorders, autoantigen-specific responses are induced by the activation of specific T cells with self peptides displayed on activated antigen presenting cells (APCs). These T cells may then activate and drive B cell responses that either initiate or contribute to chronic disease pathogenesis. In order to activate the T cell, two signals are required: T cell receptor (TCR) engagement by autoantigen presented in the context of self MHC class II and costimulation (CD28-CD80 / CD86 interactions). Feedback must also be provided to the APC through MHC class II engagement by the TCR and through costimulatory events controlling T cell differentiation and effector function (CD154-CD40 interactions, among others). With this in mind, numerous strategies have been developed to block the engagement and activation of self-reactive cells. We review and discuss recent progress in understanding the efficacy and underlying molecular mechanisms of three separate immunotherapeutic strategies targeting the TCR and costimulatory molecules: i) blocking TCR signaling (using non-mitogenic anti-CD3 monoclonal antibody); ii) blocking CD28 costimulation (anti-B7 monoclonal antibody blockade); and iii) blocking CD40 engagement on APCs (anti-CD154 monoclonal antibody blockade).

Keywords: autoimmunity, inflammation, co-stimulation, blockade, therapy, t cell receptor, cd3, cd28, cd40, cd80

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy